Wai Chun Bio-Technology (HKG:0660) will hold an extraordinary general meeting on April 30 to vote on the company's proposed capital reorganization.
The biotech firm is planning a capital reorganization in which it will reduce the par value of each of its issued ordinary share to HK$0.01 from HK$0.25, according to a Thursday bourse filing.
The company will reduce its issued share capital by cancelling the paid-up capital of HK$0.25 on each issued ordinary share.
Following the reduction, each authorized but unissued ordinary and preference share with a par value of HK$0.25 will be divided into 25 new shares with a par value of HK$0.01 each.
After the reorganization, the company's authorized capital will become 10 billion new ordinary shares, totaling HK$100 million, and 204 million new preference shares, amounting to HK$2.04 million.
Price (HKD): $0.11, Change: $+0.0070, Percent Change: +7.14%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.